Immunoprophylaxis of Respiratory Syncytial Virus Infection: Recent Updates

The respiratory syncytial virus (RSV) has been the most prevalent cause of respiratory illness in children and infants. Although the humoral immune response usually produces anti -RSV neutralizing antibodies during an infant's initial infection, they are usually insufficient. Despite the fact that RSV -specific neutralizing antibody production remains effective during infection, humoral immunity declines with time, resulting in frequent reinfection in subsequent seasons. With high prevalence and significant morbidity in young children and older adults, currently available patient care for RSV is based on supportive therapy. RSV prevention strategies have advanced significantly as a result of ongoing studies on the immunopathology, community transmission, and mechanisms underlying the virus replication. Despite the fact that RSV and poliovirus were discovered at the same time, cost-effective vaccinations for the risk groups were unavailable in many countries.